185 related articles for article (PubMed ID: 7876505)
1. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
Tremaine WJ; Schroeder KW; Harrison JM; Zinsmeister AR
J Clin Gastroenterol; 1994 Dec; 19(4):278-82. PubMed ID: 7876505
[TBL] [Abstract][Full Text] [Related]
2. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
3. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
4. Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
Mahmud N; Kamm MA; Dupas JL; Jewell DP; O'Morain CA; Weir DG; Kelleher D
Gut; 2001 Oct; 49(4):552-6. PubMed ID: 11559654
[TBL] [Abstract][Full Text] [Related]
5. Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis.
Schreiber S; Howaldt S; Raedler A
Gut; 1994 Aug; 35(8):1081-5. PubMed ID: 7926910
[TBL] [Abstract][Full Text] [Related]
6. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
[TBL] [Abstract][Full Text] [Related]
8. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
[TBL] [Abstract][Full Text] [Related]
9. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
[TBL] [Abstract][Full Text] [Related]
10. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
11. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
12. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
Sninsky CA; Cort DH; Shanahan F; Powers BJ; Sessions JT; Pruitt RE; Jacobs WH; Lo SK; Targan SR; Cerda JJ
Ann Intern Med; 1991 Sep; 115(5):350-5. PubMed ID: 1863024
[TBL] [Abstract][Full Text] [Related]
13. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
14. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease.
Griffiths A; Koletzko S; Sylvester F; Marcon M; Sherman P
J Pediatr Gastroenterol Nutr; 1993 Aug; 17(2):186-92. PubMed ID: 8229546
[TBL] [Abstract][Full Text] [Related]
15. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease.
Singleton JW; Hanauer S; Robinson M
Dig Dis Sci; 1995 May; 40(5):931-5. PubMed ID: 7729281
[TBL] [Abstract][Full Text] [Related]
16. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
[TBL] [Abstract][Full Text] [Related]
17. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
[TBL] [Abstract][Full Text] [Related]
18. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
[TBL] [Abstract][Full Text] [Related]
19. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Martin F
Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
[TBL] [Abstract][Full Text] [Related]
20. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
